Please login to the form below

Not currently logged in
Email:
Password:

Amgen appoints Jonathan M Peacock as CFO

Amgen has appointed Jonathan M Peacock to the role of chief financial officer with effect from September 1, 2010

Amgen has appointed Jonathan M Peacock to the role of chief financial officer (CFO) with effect from September 1, 2010. He will take over the role from Michael A Kelly, who has served as acting CFO since May 2010. Peacock will have responsibility for Amgen's finance and investor relations operations, and will report to Amgen's chairman and CEO, Kevin W Sharer.

Peacock will join from Novartis, where he has held the role of CFO and administration officer since 2005, leading the finance, information technology, purchasing, strategic planning and mergers and acquisitions functions.

Speaking about the appointment, Sharer said: "I am delighted to have a leader of Jonathan's talent, vision and international experience join Amgen at a time when we are expanding globally."

A qualified accountant with an MA in economics from the University of St Andrews in Scotland, Peacock has previous experience as a partner at McKinsey and Company, where he was co-leader of the European corporate finance practice working in the consulting firm's Amsterdam, Zurich and London offices. He was also a partner at Price Waterhouse in New York and London. 

15th July 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics